130 related articles for article (PubMed ID: 38537953)
21. Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid.
Zhang G; Yu X; Zhu L; Fan Q; Shi H; Lang J
BMC Cancer; 2020 Jun; 20(1):514. PubMed ID: 32493236
[TBL] [Abstract][Full Text] [Related]
22. Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.
Dhingra S; Rodriguez ME; Shen Q; Duan X; Stanton ML; Chen L; Zhang R; Brown RE
Int J Clin Exp Pathol; 2010 Jan; 4(2):134-46. PubMed ID: 21326806
[TBL] [Abstract][Full Text] [Related]
23. The Role of Endometrial Biopsy in the Preoperative Detection of Uterine Leiomyosarcoma.
Hinchcliff EM; Esselen KM; Watkins JC; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Quade BJ; Muto MG
J Minim Invasive Gynecol; 2016; 23(4):567-72. PubMed ID: 26851414
[TBL] [Abstract][Full Text] [Related]
24. The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9.
Wang X; Yang B; She Y; Ye Y
J Cell Biochem; 2018 Sep; 119(9):7790-7799. PubMed ID: 29904939
[TBL] [Abstract][Full Text] [Related]
25. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
26. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
[TBL] [Abstract][Full Text] [Related]
27. Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
Sahly NN; Banaganapalli B; Sahly AN; Aligiraigri AH; Nasser KK; Shinawi T; Mohammed A; Alamri AS; Bondagji N; Elango R; Shaik NA
Syst Biol Reprod Med; 2021 Jun; 67(3):209-220. PubMed ID: 33685300
[TBL] [Abstract][Full Text] [Related]
28. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
[TBL] [Abstract][Full Text] [Related]
29. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
McNamara B; Harold J; Manavella D; Bellone S; Mutlu L; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Yang K; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Burton EA; Inagaki H; Albers A; Zhang C; Bollag G; Schlessinger J; Santin AD
Gynecol Oncol; 2023 May; 172():65-71. PubMed ID: 36958197
[TBL] [Abstract][Full Text] [Related]
30. Oncological outcomes of unexpected uterine leiomyosarcoma: A single-center retrospective analysis of 5528 consecutive hysterectomies.
Casarin J; Ghezzi F; Lembo A; Artuso V; Schivardi G; Galati EF; Ambrosoli AL; Bogani G; Multinu F; Cromi A
J Surg Oncol; 2024 Mar; 129(3):517-522. PubMed ID: 37974522
[TBL] [Abstract][Full Text] [Related]
31. A nutrient mixture reduced tumor growth of SK-UT-1 human leiomyosarcoma cells in vivo and in vitro by inhibiting MMPs and inducing apoptosis.
Roomi MW; Bhanap B; Niedzwiecki A; Rath M
Exp Oncol; 2021 Sep; 43(3):209-216. PubMed ID: 34591419
[TBL] [Abstract][Full Text] [Related]
32. [The differential diagnosis between uterine leiomyosarcoma and the special subtypes of leiomyoma].
Zhu XQ; Shi YF; Cheng XD; Wu YZ
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(16):1419-21. PubMed ID: 14521746
[TBL] [Abstract][Full Text] [Related]
33. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization.
Levy B; Mukherjee T; Hirschhorn K
Cancer Genet Cytogenet; 2000 Aug; 121(1):1-8. PubMed ID: 10958933
[TBL] [Abstract][Full Text] [Related]
34. Ki67 as a prognostic marker in uterine leiomyosarcoma: A quantitative systematic review.
Travaglino A; Raffone A; Catena U; De Luca M; Toscano P; Del Prete E; Vecchione ML; Lionetti R; Zullo F; Insabato L
Eur J Obstet Gynecol Reprod Biol; 2021 Nov; 266():119-124. PubMed ID: 34624740
[TBL] [Abstract][Full Text] [Related]
35. Biomarker resolution of uterine smooth muscle tumor necrosis as benign vs malignant.
Yang EJ; Mutter GL
Mod Pathol; 2015 Jun; 28(6):830-5. PubMed ID: 25698060
[TBL] [Abstract][Full Text] [Related]
36. Functionality of the Tumor Suppressor
Stope MB; Cernat V; Kaul A; Diesing K; Koensgen D; Burchardt M; Mustea A
Anticancer Res; 2018 Mar; 38(3):1547-1550. PubMed ID: 29491084
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new.
Hwang H; Matsuo K; Duncan K; Pakzamir E; Pham HQ; Correa A; Fedenko A; Mhawech-Fauceglia P
J Clin Pathol; 2015 Sep; 68(9):710-7. PubMed ID: 25991737
[TBL] [Abstract][Full Text] [Related]
38. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
39. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
[TBL] [Abstract][Full Text] [Related]
40. Fumarate Hydratase and S-(2-Succinyl)-Cysteine Immunohistochemistry Shows Evidence of Fumarate Hydratase Deficiency in 2% of Uterine Leiomyosarcomas: A Cohort Study of 348 Tumors.
Chapel DB; Sharma A; Maccio L; Bragantini E; Zannoni GF; Yuan L; Quade BJ; Parra-Herran C; Nucci MR
Int J Gynecol Pathol; 2023 Mar; 42(2):120-135. PubMed ID: 36729957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
